Neoadjuvant Trastuzumab Induces Apoptosis in Primary Breast Cancers
- 10 April 2005
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (11), 2460-2468
- https://doi.org/10.1200/jco.2005.00.661
Abstract
Greater understanding of the cellular response in trastuzumab-treated patients will provide insight into the clinical management of patients. We performed a neoadjuvant trial in 35 patients with locally advanced HER-2/neu overexpressing breast cancers who received weekly trastuzumab given as a single agent for the first 3 weeks, followed by a combination of trastuzumab and docetaxel for 12 weeks before surgery. Sequential core biopsies were taken at baseline and within weeks 1 and 3 after the first dose of trastuzumab. Clinical response to trastuzumab was assessed by tumor measurements on day 22 before chemotherapy. Core biopsies were assessed by immunohistochemistry for cell cycle and proliferation (Ki67, p27, phosphorylated [p] -MAPK), apoptosis and survival (apoptotic index, p-Akt), epidermal growth factor receptor, and total and p-HER-2. There was early tumor regression with a median decrease of −20.0% (range. 0% to 60.4%) after only 3 weeks of trastuzumab, and eight patients (23%) had a partial response. Consistent with the clinical regressions, apoptosis was significantly induced (median increase from 3.5% to 4.7%; P = .006) within week 1, a 35% increase above baseline. No significant change in epidermal growth factor receptor score was observed in week 1, without changes in total or p-HER-2 expression. Tumors with high baseline Ki67 were less likely to respond (P = .02). In primary breast cancers, trastuzumab substantially induces apoptosis, providing a molecular explanation for both its therapeutic efficacy and its successful combination with cytotoxic chemotherapy.Keywords
This publication has 20 references indexed in Scilit:
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer CellsCancer Research, 2004
- Studies of the Potential Utility of Ki67 as a Predictive Molecular Marker of Clinical Response in Primary Breast CancerBreast Cancer Research and Treatment, 2003
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Biological Effects of Anti-ErbB2 Single Chain Antibodies Selected for Internalizing FunctionBiochemical and Biophysical Research Communications, 2001
- Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinomaCancer, 2000
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathwayOncogene, 1997
- Cell kinetics in human breast cancer: Comparison between the prognostic value of the cytofluorimetric S‐phase fraction and that of the antibodies to Ki‐67 and PCNA antigens detected by immunocytochemistryInternational Journal of Cancer, 1994